May 9, 2019

Altavant Sciences to Provide Clinical Update at 2019 Respiratory Innovation Summit

Cary, N.C. and BASEL, Switzerland — May 9, 2019 — Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension (PAH) and other indications, today announced that it has been invited to present at the 2019 Respiratory Innovation Summit (RIS) being held May 17 in Dallas, […] Read More »

January 31, 2019

Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress

Basel, Switzerland and Durham, N.C. — Jan. 31, 2019 — Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension (PAH) and other indications, will present its latest nonclinical and clinical data at the Pulmonary Vascular Research Institute (PVRI) 13th Annual World Congress on Pulmonary Vascular […] Read More »

January 2, 2019

Altavant Sciences Appoints Lyn Baranowski Chief Operating Officer

BASEL, Switzerland and DURHAM, N.C. — Jan. 2, 2019 — Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension and other indications, today announced the appointment of Lyn Baranowski as Chief Operating Officer. In this new position, she will be involved in the general management of […] Read More »

Media

Roivant Pipeline Day

Altavant CEO Bill Symonds presents

Get in Contact

info@altavant.com